These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36191861)

  • 1. Engineering the right formulation for enhanced drug delivery.
    Ke WR; Chang RYK; Chan HK
    Adv Drug Deliv Rev; 2022 Dec; 191():114561. PubMed ID: 36191861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optical photothermal infrared spectroscopy for nanochemical analysis of pharmaceutical dry powder aerosols.
    Khanal D; Kim J; Zhang J; Ke WR; Holl MMB; Chan HK
    Int J Pharm; 2023 Feb; 632():122563. PubMed ID: 36586629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical stability of dry powder inhaler formulations.
    Shetty N; Cipolla D; Park H; Zhou QT
    Expert Opin Drug Deliv; 2020 Jan; 17(1):77-96. PubMed ID: 31815554
    [No Abstract]   [Full Text] [Related]  

  • 5. Elucidation of the effect of added fines on the performance of dry powder inhalation formulations.
    Stankovic-Brandl M; Radivojev S; Sailer P; Penz FK; Paudel A
    Int J Pharm; 2022 Dec; 629():122359. PubMed ID: 36332830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the Surface Roughness Length Scales of Lactose Carrier Particles in Dry Powder Inhalers.
    Tan BMJ; Chan LW; Heng PWS
    Mol Pharm; 2018 Apr; 15(4):1635-1642. PubMed ID: 29490144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
    Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in lactose blend formulations for carrier-based dry powder inhalation.
    Hebbink GA; Jaspers M; Peters HJW; Dickhoff BHJ
    Adv Drug Deliv Rev; 2022 Oct; 189():114527. PubMed ID: 36070848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance indicators for carrier-based DPIs: Carrier surface properties for capsule filling and API properties for in vitro aerosolisation.
    Faulhammer E; Zellnitz S; Wutscher T; Stranzinger S; Zimmer A; Paudel A
    Int J Pharm; 2018 Jan; 536(1):326-335. PubMed ID: 29217472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spray-Dried PulmoSphere™ Formulations for Inhalation Comprising Crystalline Drug Particles.
    Weers JG; Miller DP; Tarara TE
    AAPS PharmSciTech; 2019 Feb; 20(3):103. PubMed ID: 30734187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dry powders for oral inhalation free of lactose carrier particles.
    Healy AM; Amaro MI; Paluch KJ; Tajber L
    Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance.
    Stegemann S; Faulhammer E; Pinto JT; Paudel A
    Int J Pharm; 2022 Feb; 614():121445. PubMed ID: 34998921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
    Lin YW; Wong J; Qu L; Chan HK; Zhou QT
    Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics.
    Chang RYK; Chan HK
    Pharm Res; 2022 Dec; 39(12):3047-3061. PubMed ID: 36071354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spray-Congealing and Wet-Sieving as Alternative Processes for Engineering of Inhalation Carrier Particles: Comparison of Surface Properties, Blending and In Vitro Performance.
    Pinto JT; Zellnitz S; Guidi T; Schiaretti F; Schroettner H; Paudel A
    Pharm Res; 2021 Jun; 38(6):1107-1123. PubMed ID: 34114162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations.
    Kinnunen H; Hebbink G; Peters H; Shur J; Price R
    AAPS PharmSciTech; 2014 Aug; 15(4):898-909. PubMed ID: 24756910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networks.
    Kinnunen H; Hebbink G; Peters H; Shur J; Price R
    AAPS PharmSciTech; 2014 Aug; 15(4):1009-20. PubMed ID: 24831088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.